Sarepta Therapeutics Stock News

ACADIA (ACAD) to resubmit sNDA for Nuplazid (pimavanserin) to the FDA for treating hallucinations and delusions associated with dementia focused on Alzheimer's disease psychosis. Shares rise.

The momentum in the equity markets is expected to stay on firm-footing in 2022. DQ, PINS, SRPT, YY and CD have a chance to outperform next year.

Brokerages forecast that Sarepta Therapeutics, Inc. (NASDAQ:SRPT) will announce ($1.02) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for Sarepta Therapeutics earnings, with estimates ranging from ($1.39) to ($0.64). Sarepta Therapeutics posted earnings per share of ($2.40) in the same quarter last year, which would suggest a []

Oppenheimer upgraded shares of Sarepta Therapeutics (NASDAQ:SRPT) from a market perform rating to an outperform rating in a report issued on Thursday, Price Targets.com reports. The brokerage currently has $125.00 price target on the biotechnology companys stock. A number of other research firms have also recently issued reports on SRPT. Credit Suisse Group upped their [] The post Sarepta Therapeutics (NASDAQ:SRPT) Lifted to Outperform at Oppenheimer appeared first on ETF Daily News .

Wall Street analysts expect that Sarepta Therapeutics, Inc. (NASDAQ:SRPT) will post sales of $192.62 million for the current quarter, according to Zacks Investment Research. Five analysts have provided estimates for Sarepta Therapeutics earnings, with the highest sales estimate coming in at $201.70 million and the lowest estimate coming in at $175.25 million. Sarepta Therapeutics posted [] The post $192.62 Million in Sales Expected for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) This Quarter appeared first on ETF Daily News .

Sarepta Therapeutics (NASDAQ:SRPT) was upgraded by stock analysts at Oppenheimer from a market perform rating to an outperform rating in a research report issued to clients and investors on Thursday, Analyst Price Targets reports. The firm presently has a $125.00 price objective on the biotechnology companys stock. Oppenheimers price objective indicates a potential upside of []

Fifth Third Bancorp purchased a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 1,000 shares of the biotechnology companys stock, valued at approximately $92,000. Other hedge funds also recently made changes to their positions in the []

Related Stocks: AMGN , NVAX , ITCI , SRPT , BGNE , GH , ALKS , AZN , CRBU , CRL , RLYB , BHVN , ALLK , BPMC , BBIO , IOVA , DCPH , REPL ,

Related Stocks: IDXX , SRPT , MOH , ZTS , AZN , LH , MRNA , GH , ICLR , JAZZ , RLYB , FUSN , VRTX , AMED , ALXN , CNC , INCY , IOVA ,

Related Stocks: AMGN , GH , IDXX , ALNY , NVAX , SRPT , ICLR , BHVN , CTLT , CRBU , AZN , RLYB , ABT , ASND , NBIX , DXCM , ARNA , ARGX , DCPH , BBIO , RMD , BPMC , ALLK , IOVA ,

The Antisense Oligonucleotide Therapies Market research report provides market forecast information, considering the history of the industry, the future of the industry with respect to what situation it may face, it will grow or it will fail. Inputs of various

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has been assigned a consensus rating of Buy from the twenty-two research firms that are covering the stock, Marketbeat Ratings reports. Ten research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The average twelve-month price target among brokers that have []

NEXT Financial Group Inc cut its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 14.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,629 shares of the biotechnology companys stock after selling 267 shares during the quarter. NEXT Financial Group Incs []

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?